Showing 2671-2680 of 5956 results for "".
- VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Productshttps://modernod.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan. “We’re very excited to work with Wak
- National Eye Institute Launches Data Portal for Macular Degeneration Researchhttps://modernod.com/news/national-eye-institute-launches-data-portal-for-macular-degeneration-research/2478992/The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease
- CooperVision: Clariti 1 day Becomes First Net Plastic Neutral Contact Lens in the UShttps://modernod.com/news/coopervision-clariti-1-day-becomes-first-net-plastic-neutral-contact-lens-in-the-us/2478971/To provide an easy way for eye care professionals and their patients to be more sustainable, CooperVision announced a partnership with Plastic Bank that makes its clariti 1 day family the first net plastic neutral contact lenses.1 Plastic Bank is a social enterprise that builds
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDhttps://modernod.com/news/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-gene-therapy-in-wet-amd/2478955/Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal (IVT) injection gene therapy for the treatment of wet age-related macular degeneration (AMD
- Santen EMEA Leads Awareness Campaign to Prioritize Their Glaucoma During the Pandemichttps://modernod.com/news/santen-emea-leads-awareness-campaign-to-prioritize-their-glaucoma-during-the-pandemic/2478942/Santen, along with a group of patient advocacy groups across Europe, is leading a multi-channel awareness campaign to encourage patients to prioritize their glaucoma during the pandemic. The on-and-offline campaign, w
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- Essilor Mourns Passing of Bernard Maitenaz, Inventor of the First Varilux Progressive Lenshttps://modernod.com/news/essilor-mourns-passing-of-bernard-maitenaz-inventor-of-the-first-varilux-progressive-lens/2478895/Essilor announced that Bernard Maitenaz, the inventor of the Varilux progressive lens that improved the lives of millions of presbyopes globally and redefined an entire industry, has passed away in his home city of Paris at the age of 94. Bernard Maitenaz’s pioneering work revolutionized